BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 32190895)

  • 1. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
    Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.
    Wang J; Ye C; Liu J; Hu Y
    Biochem Biophys Res Commun; 2018 Jul; 501(4):1034-1040. PubMed ID: 29777711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis.
    Eoh KJ; Lee SH; Kim HJ; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
    Biochem Biophys Res Commun; 2018 Mar; 497(2):513-520. PubMed ID: 29452092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
    Ge T; Liu T; Guo L; Chen Z; Lou G
    Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.
    Yan M; Yang X; Shen R; Wu C; Wang H; Ye Q; Yang P; Zhang L; Chen M; Wan B; Zhang Q; Xia S; Lu X; Shao G; Zhou X; Yu J; Shao Q
    Cell Death Dis; 2018 Nov; 9(11):1123. PubMed ID: 30409964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SMAD3 inducing the transcription of  STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel.
    Shi Y; Zhang J; Liu M; Huang Y; Yin L
    J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
    Dai J; Wei R; Zhang P; Kong B
    J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
    Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
    EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. microRNA-671-5p reduces tumorigenicity of ovarian cancer via suppressing HDAC5 and HIF-1α expression.
    Peng D; Wu T; Wang J; Huang J; Zheng L; Wang P; Li J; Wu L; Luo M
    Chem Biol Interact; 2022 Mar; 355():109780. PubMed ID: 34990588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of Hypoxia-Inducible Factor 1α (HIF-1α) Promotes Autophagy and Inhibits Phosphatidylinositol 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Signaling Pathway in Ovarian Cancer Cells.
    Huang J; Gao L; Li B; Liu C; Hong S; Min J; Hong L
    Med Sci Monit; 2019 Jun; 25():4250-4263. PubMed ID: 31175269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulated expression of miR-134 contributes to paclitaxel resistance in human ovarian cancer cells.
    Shuang T; Wang M; Shi C; Zhou Y; Wang D
    FEBS Lett; 2015 Oct; 589(20 Pt B):3154-64. PubMed ID: 26363097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexmedetomidine Regulates Proliferation, Apoptosis, Migration, and Invasion in Ovarian Cancer Cells via MiR-155-HIF-1α Axis.
    Zheng L; Jia R; Zhao J
    Med Sci Monit; 2019 Dec; 25():10164-10172. PubMed ID: 31887107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-181c sensitizes ovarian cancer cells to paclitaxel by targeting GRP78 through the PI3K/Akt pathway.
    Zhang LY; Yu JY; Leng YL; Zhu RR; Liu HX; Wang XY; Yang TT; Guo YN; Tang JL; Zhang XC
    Cancer Gene Ther; 2022 Jun; 29(6):770-783. PubMed ID: 34145425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upregulation of miR-34c after silencing E2F transcription factor 1 inhibits paclitaxel combined with cisplatin resistance in gastric cancer cells.
    Zheng H; Wang JJ; Yang XR; Yu YL
    World J Gastroenterol; 2020 Feb; 26(5):499-513. PubMed ID: 32089626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bufalin inhibits ovarian carcinoma via targeting mTOR/HIF-α pathway.
    Su S; Dou H; Wang Z; Zhang Q
    Basic Clin Pharmacol Toxicol; 2021 Feb; 128(2):224-233. PubMed ID: 32905663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells.
    Weiner-Gorzel K; Dempsey E; Milewska M; McGoldrick A; Toh V; Walsh A; Lindsay S; Gubbins L; Cannon A; Sharpe D; O'Sullivan J; Murphy M; Madden SF; Kell M; McCann A; Furlong F
    Cancer Med; 2015 May; 4(5):745-58. PubMed ID: 25684390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.